🇺🇸·1d agoIndustry
AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
Publisher
A
AbbVie News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.abbvie.com
Leave the platform to read the original full article on the publisher site.
Source: AbbVie News
Scope: Industry
Related coverage
More related coverage
Recordati·4h ago
RECORDATI: THE SHAREHOLDERS’ MEETING APPROVES THE 2025 FINANCIAL STATEMENTS AND THE DIVIDEND OF €1.34 PER SHARE (+5.5% VS. 2024). NEW BOARD OF STATUTORY AUDITORS APPOINTED
Hyman, Phelps & McNamara (FDA Law)·12h ago
CRL Release Update – No litigation war yet, but new Citizen Petition beats the drums
Natco Pharma·15h ago
natco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26
Natco Pharma·15h ago